Ispire Technology (ISPR) risk factors
Item 1A of every Ispire Technology Inc. 10-K on file, and what changed from one year to the next.
- FY2026 10-K risk factors
51 risks, 7 new, 1 dropped, 2 reworded since the prior year. Seven new risks center on pre-revenue joint ventures, FDA approval of IKE technology, cash needs, and potential loss of invested capital.
Filed Sep 15, 2026 - FY2025 10-K risk factors
45 risks, 2 new, 2 dropped, 4 reworded since the prior year. The company added specific risks regarding tariffs on imports from China and Malaysia and customer credit risks in the cannabis sector. Net losses widened significantly to $39.2 million for the year ended June 30, 2025. Allowance for credit losses increased sharply to $18.0 million.
Filed Sep 15, 2025 - FY2024 10-K risk factors
45 risks. Ispire faces heavy losses, with a net loss of $14.8 million for the fiscal year ended June 30, 2024. Operations rely heavily on related party Shenzhen Yi Jia for manufacturing and a single distributor generating up to 32.4% of revenue. The company is exposed to intense regulatory scrutiny in the nicotine and cannabis vaping markets.
Filed Sep 27, 2024